News Category
In vitro ADME studies are becoming essential for efficient drug development, helping to identify promising candidates early and avoid costly late-stag...
A new study reveals that the risk of sepsis, meningitis, or pneumonia from air pollution depends on an individual's bacterial strains, highlighting th...
Peptide Wholesale Supply has extended its HPLC peptide testing protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, aiming to improve ba...
Medical experts are urging small cell lung cancer patients to ask about clinical trials at their first appointment, as emerging treatments offer new h...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial could lead to an additional qualified source of m...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers overcome stability, targetin...
BioCorRx Inc. appoints Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory Bo...
Regentis Biomaterials reported a reduced net loss for the first half of 2026 and progress in its pivotal U.S. trial for GelrinC, a potential off-the-s...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug that aims to protect and ...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and an FD...
VERAXA Biotech has named Dr. Christoph Erkel as chief scientific officer to lead the advancement of its BiTAC® technology and oncology pipeline, a mov...
Optimi Health Corp. will initiate a Health Canada-authorized Phase 2 clinical trial in 2027 to evaluate psilocybin-assisted therapy for major depressi...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor for multiple sclerosis, is moving toward a Phase 2 trial following FDA clea...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and po...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis treatment designed to shield a...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, drawing attention to the compan...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting cancer drug ONC010, which uses synthetic lethality and nanoparticle delivery to pote...
Quantum BioPharma's Lucid-MS has received FDA clearance for a Phase 2 trial in multiple sclerosis, marking a significant step for a novel treatment ap...
An expert highlights the overlooked complexities of urinary tract infections (UTIs), stressing the need for advanced diagnostic tools to prevent misdi...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum highlights progress in its nose-to-brain drug delivery platform, with new stabi...
Quantum BioPharma announced FDA clearance for its Phase 2 trial of Lucid-MS, a first-in-class candidate for multiple sclerosis, which has drawn analys...
Quantum BioPharma Ltd. has received FDA clearance to begin a Phase 2 clinical trial for its multiple sclerosis drug candidate Lucid-MS, a milestone th...
GeoVax applauds the new Gavi-funded global mpox vaccine stockpile as a step toward sustained preparedness, while highlighting its GEO-MVA candidate's ...
VERAXA Biotech (NASDAQ: VRXA) has named veteran financial executive Raju Willener as CFO, effective immediately, to support its capital strategy and a...
Scinai Immunotherapeutics has ended its PC111 license agreement with PinCell to focus resources on its NanoAb platform and expanding CDMO business, ai...
Onco-Innovations Ltd. advances its oncology pipeline with key milestones in manufacturing, IND-enabling activities, partnerships, and funding, positio...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a potential breakthrough in multiple sclerosis treatment by targeting myeli...
A new study from Washington University School of Medicine highlights the growing role of laser interstitial thermal therapy (LITT) in brain cancer tre...
Ocumetics Technology Corp. has initiated patient recruitment for its Group Two human clinical study, marking a critical step in evaluating the safety ...
Quantum BioPharma's Lucid-MS, a first-in-class drug candidate for multiple sclerosis, has received FDA clearance for Phase 2 trials, potentially marki...
NanoViricides has registered its Phase II clinical trial for NV-387 Oral Gummies as a treatment for Ebola in the Democratic Republic of Congo, marking...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of its investigational multiple sclerosis drug Lucid-MS, a first-in-class candid...
Quantum BioPharma received FDA clearance to begin a Phase 2 trial for Lucid-MS, a novel multiple sclerosis treatment, marking a significant step towar...
Quantum BioPharma's Lucid-MS has received FDA clearance for a Phase 2 trial in MS, marking a step toward a targeted treatment for demyelination.
Tonix Pharmaceuticals has promoted Thomas Englese to Chief Commercial Officer to lead commercialization efforts for its fibromyalgia treatment TONMYA ...
A large study reveals that colorectal cancer patients who develop brain metastases have shorter survival, with timing significantly impacting prognosi...
Onco-Innovations reports significant progress in developing ONC010, a PNKP inhibitor for cancer therapy, including high-purity API production and plan...
OS Therapies is set to engage with investors at the Moody Capital conference while approaching critical regulatory decisions and data readouts for its...
A preclinical study suggests that administering immunotherapy before tumor removal surgery could improve treatment outcomes for glioblastoma patients,...
The FDA's failure to aggressively combat the illegal online sale of retatrutide, an unapproved investigational drug, has led to a dangerous black mark...
New research from Mass General Brigham shows that unintended radiation exposure to the thymus during lung cancer treatment is associated with worse cl...
Tonix Pharmaceuticals will showcase its CNS and immunology pipeline at the Cantor 2026 Global Healthcare Conference, highlighting recent approvals and...
NurExone Biologic will showcase its exosome-based therapeutic platform and U.S. initiatives at a New York conference, highlighting progress toward cli...
CNS Pharmaceuticals' Chief Business Officer discussed the company's focused pipeline strategy and deal-making criteria, signaling a disciplined approa...
Salman Fazal, MD, a hematologist and transplant specialist at UPMC Hillman Cancer Center in Harrisburg, has been named a 2026 Castle Connolly Top Doct...
Quantum BioPharma's Lucid-MS candidate for progressive multiple sclerosis earns a 'Buy' rating and $8 price target from Rodman & Renshaw, highlighting...
NanoViricides is progressing its measles treatment NV-387 to Phase II trials, leveraging FDA designations, as measles cases surge globally.
